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Background/aim: Noonan syndrome is an autosomal dominant disorder with an incidence of 1/1000–2500. It results from proteintyrosine phosphatase, nonreceptor type 11 (PTPN11) mutations in roughly 50% of cases. Mutational screening of PTPN11 has been
carried out in different populations. Thus, the aim of this study was to screen, for the first time, PTPN11 mutations in a series of
Moroccan Noonan syndrome patients.
Materials and methods: We used bidirectional sequencing of exons 3 and 8, considered as PTPN11 mutation hot spots, and then
compared the rate of mutational events of these exons between different populations using chi-square and Fisher’s exact tests.
Results: We detected 3 heterozygous mutations (Asp61Gly, Tyr63Cys, and Asn308Ser) in 4 individuals of 16 sporadic patients (25%).
The rate of mutation in our cohort did not differ from that of other populations. However, we found significant differences in the
mutation rate of exon 8 between one Japanese cohort and some populations, which requires more investigations to be explained.
Conclusion: The present study allowed identification of mutations clustered in exons 3 and 8 of the PTPN11 gene in a Moroccan
Noonan syndrome cohort and enabled us to give appropriate genetic counseling to the mutation-positive patients.
Key words: Noonan syndrome, PTPN11, mutation analysis, SHP-2, mutation rate comparison

1. Introduction
Noonan syndrome (NS, OMIM 163950) is a common
autosomal dominant disorder with an estimated incidence
of 1 in 1000–2500 live births. Clinically, it is characterized
by short stature, facial dysmorphia (e.g., hypertelorism,
down-slanting palpebral fissures, low-set posteriorly
rotated ear), skeletal defects (e.g., chest deformities),
congenital heart defects (especially pulmonary valve
stenosis) (1,2), and other features, occasionally observed,
such mild mental retardation, cryptorchidism, and
bleeding diathesis. However, there is no defined clinical
diagnosis of this syndrome because of the high variation
level of the phenotypic expression with age and between
individuals (3).
Tartaglia et al. (4) demonstrated, using a positional
candidacy approach, that heterozygous missense mutations
in the protein-tyrosine phosphatase, nonreceptor type 11
(PTPN11) (MIM 176876) are responsible for Noonan
syndrome in 50% of patients. The PTPN11 gene mapped
on chromosome 12q24 contains 15 exons and encodes the
* Correspondence: ihssane.elbouchikhi@usmba.ac.ma
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cytoplasmic nonreceptor protein tyrosine phosphatase
(SHP-2) with 2 tandemly arranged amino-terminal srchomology 2 (SH2) domains (N-SH2 and C-SH2) and a
protein-tyrosine phosphatase (PTP) domain (5,6).
The PTPN11 gene is widely expressed in human
tissues, especially in the heart, brain, and skeletal muscle.
Indeed, it is involved in the regulation of the ubiquitous
RAS–MAPK (mitogen activated protein kinase) signaling
cascade, mediated by growth factors, cytokines, and
hormones (7).
Crystallographic data on SHP-2 indicate that in the
default inactive condition, the usual interaction between
N-SH2 and PTP domains of SHP-2 hide the catalytic
site. However, the missense mutations clustering in
these domains cause changes in the SHP-2 conformation
leading to the emergence of catalytic site. Thus, the SHP-2
active conformation keeps upregulating the RAS-MAPK
pathway and generates NS features (4,8).
To date, several studies have been performed to describe
PTPN11 mutation patterns in specific populations, such as
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Italian (9), Japanese (10), Korean (11),Taiwanese (12), and
Brazilian (13) populations, amongst others. Thus, in order
to define, for the first time, the spectrum of mutations
and clinical features in Moroccan children with Noonan
syndrome, we carried out mutation screening of the most
common PTPN11 exons (and their intron boundaries)
affected by mutations in 16 Moroccan patients with
sporadic NS.
2. Materials and methods
2.1. Clinical evaluation
Noonan syndrome was diagnosed by the presence of the
major clinical characteristics (typical facial dysmorphia,
pulmonic stenosis or abnormal electrocardiogram
pattern, pterygium colli, pectus carinatum/excavatum,
short stature, and cryptorchidism in male subjects) and
minor criteria (psychomotor retardation or speech delay,
bleeding diathesis, family history of Noonan syndrome,
and other additional features). According to the van der
Burgt criteria (14), patients with at least typical facial
dysmorphia associated with 1 major or 2 minor signs, or
suggestive facial dysmorphism associated with 2 major
or 3 minor signs, were enrolled from the Departments of
Medical Genetics and Pediatrics between January 2009 and
June 2013. Nineteen patients were identified as affected by
NOONAN syndrome. Echocardiography and karyotyping
were carried out routinely for affected individuals.
2.2. Mutational analysis
After obtaining informed consent, peripheral blood was
obtained from each patient and genomic DNA samples
were extracted from blood lymphocytes using the
GeneCatcher Magnetic Beads Kit (Invitrogen). For each
patient, both PTPN11 exons 3 and 8, which are considered
as mutation hot spots (4,11), were individually amplified
by polymerase chain reaction (PCR) using 2 pairs of
corresponding primers derived from published data (15).
PCR was performed in a 25-mL reaction volume
containing 60 ng of genomic DNA, 5 U of Taq (Invitrogen),
20 pmol of each primer, 50 mM MgCl2, 10 mM dNTP, and
10X PCR buffer (Invitrogen) in the Veriti 96-well Thermal
Cycler 9902 (Applied Biosystems). The PCR cycling
conditions were 94 °C for 8 min; 35 cycles of 94 °C for 45 s,
63 °C (exon 3) or 58 °C (exon 8) for 45 s, and 72 °C for 45
s; and 72 °C for 10 min.
Bidirectional direct sequencing of purified PCR
products was performed using the BigDye Terminator
V1.1 Cycle Sequencing Kit (ABI Prism) and an Applied
Biosystems 3500Dx Genetic Analyzer. The chromatogram
was analyzed by the Sequencing Analysis SeqA v.5.4
(Applied Biosystems). The sequences thus obtained
underwent bioinformatics analysis using the “Nucleotide
Blast” alignment program at http://blast.ncbi.nlm.nih.gov.

2.3. Statistical analysis
Comparisons between study cohorts were done using chisquare tests for >5 and Fisher’s exact test for smaller cohort
sizes.
3. Results
In this study, 19 individuals were identified to be affected
by Noonan syndrome according to the van Der Burgt
criteria. Of those, 16 subjects were screened for PTPN11
mutations, while the 3 remaining could not be reached. All
subjects had normal karyotypes with 46,XX for females
and 46,XY for males.
3.1. Mutation analysis of the PTPN11 gene
DNA from the 16 patients with Noonan syndrome were
screened for PTPN11 mutations. Exons 3 and 8 and
their flanking intron sequences, which are considered as
mutation hot spots, were PCR-amplified and bidirectionally
sequenced. We identified 3 different heterozygous missense
mutations in 4 subjects (25%). All the exonic mutations
found in our series led to amino acid residue changes and
were located in the N-SH2 and PTP functional domains
(Figure 1). These mutations were previously reported
as disease-causing mutations (4). Table 1 and Figure 1
summarize mutation-screening results. Moreover, 3 other
subjects showed the same g.63899C > T substitution in
intron 7 of their PTPN11 sequences.
3.2. Clinical features
The total cohort includes 10 males (52.63%) and 9 females
(47.37%) with age ranging from 3 days to 15 years. All
cases were sporadic, and the patients’ parents have normal
phenotypes. Congenital heart disease was found in 17/19
(89.47%) patients, distributed as pulmonic stenosis
in 10/17 (58.82%), pulmonic stenosis + septal defects
in 3/17 (17.65%), pulmonic stenosis + hypertrophic
cardiomyopathy in 2/17 (11.76%), and hypertrophic
cardiomyopathy in 2/17 (11.76%). Among the 16 screened
patients with Noonan syndrome, 4 subjects had mutation.
Their clinical features are summarized in Table 1.
4. Discussion
PTPN11 mutations were demonstrated to be involved in
Noonan syndrome by Tartaglia et al. (4). This evidence
was proven afterward in the subsequent studies of different
populations. The aim of the present study was to report, for
the first time, the mutations of PTPN11 in 16 Moroccan
children using the bidirectional sequencing of the main
exons affected by mutations (exons 3 and 8), and then to
compare the frequency of mutational events of these exons
between different populations.
4.1. Mutation analysis
The molecular analysis revealed 3 different missense
mutations in 4 sporadic cases (25%). These substitutions
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Figure 1. A, B, and C- Sequencing chromatogram of the detected PTPN11 heterozygous mutations, respectively Asp61Gly,
Tyr63Cys, and Asn308Ser; D- organization of PTPN11 exons and domains and location of the 3 mutations.

were heterozygous and affected the highly conserved
residues of the N-SH2 and PTP domains. The mutation
A182G leading to the Asp61Gly substitution was observed
in 2 patients. This mutation is located in exon 3, which
encodes the N-SH2 domain. The second mutation, A188G,
resulting in the Tyr63Cys substitution, was present in one
patient. This is also located in exon 3. The third mutation
was identified in one patient at position 923A→G in exon
8 and leads to the Asn308Ser substitution in the PTP
domain. In several studies, Asn308Asp was the most
prevalent mutation, affecting codon 308 (15,16). However,
this mutation was not detected in our cohort.
The occurrence of these mutations had been proven
to be pathogenic and responsible for Noonan syndrome
manifestation. It was demonstrated (4,17) that, in the
inactive conformation, residues located in or around
the interactive surface of the N-SH2 and PTP domains
interact with each other in order to hide the catalytic site,
and their substitution disturbs the equilibrium between
active and inactive conformation, leading to the gain of
function effect and the increase of phosphatase activity in
the RAS/MAPK pathway. Effectively, crystallographic data
on inactive conformation of SHP-2 confirmed the direct
involvement of Asp61 (among others) in the stabilization
of inactive conformation (8), whereas Tyr63 and Asn308
are involved indirectly because of their closeness to the
engaged residues.
It is worth mentioning that the substitution g.63899C
> T (rs41279090:C>T) in intron 7 was identified in 3
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other subjects. This change is present frequently in control
subjects and considered as a polymorphism.
4.2. Comparison to previous studies
In this part of the study, we attempt to compare the
mutation rate of exon 3 and exon 8 in our cohort to those
of different studies, and also to compare mutation rates
of different studies to each other, in order to reveal any
putative differences.
The statistical analysis does not reveal any significant
difference in mutation rates of exon 3 and exon 8 between
our population and the other populations (Table 2).There
was also no significant difference in exon 3 mutation rate
between other populations (P = 0.1). These results suggest
that the frequency of mutational events in exon 3 and 8 of
PTPN11 seems not to be affected by ethnicity.
It is important to mention that, when comparing
the mutation rate of exon 8 between populations, we
found significant differences between some populations:
between American (4,15) and Japanese (18) populations
(respectively P = 0.04 and P = 0.01) and between German
(19) and Japanese (18) populations (P = 0.04), which
could be due to the low rate of exon 8 mutations (2.4%)
in the Japanese cohort studied by Niihori et al. (18). More
investigations are required to explain these data.
4.3. Clinical features
In our study, pulmonic stenosis was observed in all
mutated patients affected by congenital heart disease,
which confirms the previous studies that demonstrated
a significant correlation between PTPN11 mutations
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Table 1. PTPN11 mutations and clinical features in mutated patients with Noonan syndrome.
Features

Patient 1

Patient 2

Patient 3

Patient 4

Nucleotide substitution

c.182A>G

c.182A>G

c.188A>G

c.923A>G

Amino acid substitution

Asp61Gly

Asp61Gly

Tyr63Cys

Asn308Ser

- Exon / domain

Exon 3 / N-SH2

Exon 3 / N-SH2

Exon 3 / N-SH2

Exon 8 / PTP

Age (years:months)

11:0

11:3

10:7

4:8

Sex

Male

Male

Female

Female

Growth (±SD): height (cm)

Short stature

117 (–4 SD)

127 (–2.5 SD)

105 (normal)

Weight (kg)

ND

19 (–3 SD)

27 (–1 SD)

17 (normal)

Congenital heart disease

Pulmonic stenosis, ASD

Pulmonic stenosis

Normal

Pulmonic stenosis,
HCM

Triangular face

ND

+

+

+

Micrognathia

ND

+

-

+

Hypertelorism

+

+

+

+

Ptosis

ND

-

+

-

Down-slanting palpebral fissures

+

+

+

+

Low-set posteriorly rotated ears

ND

+

+

+

Nerve deafness

ND

-

-

+

Epicanthic folds

+

+

-

+

Deeply grooved philtrum

ND

+

+

+

High arched palate

ND

+

+

+

Short and webbed neck

ND

+

+

+

Low posterior hairline

ND

Articulation and learning

Learning difficulties

Chest

Chest deformity

+
Articulation and
learning difficulties
Shield chest, pectus
excavatum inferiorly

+
Articulation
difficulties
Shield chest, pectus
excavatum inferiorly

+
Articulation and
learning difficulties
Shield chest, pectus
excavatum inferiorly

Skeletal

ND

Cubitus valgus,
brachydactyly,
kyphoscoliosis

Cubitus valgus

Cubitus valgus,
brachydactyly,
clinodactyly

Hematology

ND

Bleeding diathesis

Bleeding diathesis

ND

Genital

Cryptorchidism

Cryptorchidism

-

-

Dysmorphic facies

ASD: Atrial septal defect. HCM: Hypertrophic cardiomyopathy. ND: Not determined. SD: Standard deviation.

and pulmonic stenosis (15,23). This is especially true for
the Asn308Ser mutation in patient 4 that was previously
associated with pulmonic stenosis by Sarkozy et al. (9).
This correlation was explained by the fact that SHP2 is involved in the signal transduction pathway of the
epidermal growth factor expressed in semilunar valve
development (24,25). Generally, all clinical manifestations
observed in mutated Noonan syndrome patients are
attributed to the contribution of SHP-2/PTPN11 in the
RAS–MAPK molecular signaling cascade that is essential
for cellular differentiation, proliferation, or migration
processes in most tissues (26,27).

Moreover, there were several features shared by all
subjects with PTPN11 mutations. Facial dysmorphia,
although slightly different from one patient to another,
was present in all mutation-positive patients; short stature
was seen in 75% of our mutation-positive patients; chest
deformity was present in all mutation-positive subjects;
and cryptorchidism was observed in all male patients. This
could be due to the small sample size or may be explained
by the fact that some features were initially among the
main “major criteria” of selection.
It is important to differentiate the Noonan syndrome
phenotype from the Noonan-like syndromes (Leopard
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Table 2. Reported mutation rate in PTPN11 exons 3 and 8 in different studies of patients with Noonan syndrome.
Reference study

Reference population

Exon 3

P-valuea

Exon 8

P-valuea

Tartaglia et al., 2001 (4)

American

5/22 (31.8%)

0.91

4/22 (18.2%)

0.37

Tartaglia et al., 2002 (15)

American

22/119 (18.5%)

1

21/119 (17.6%)

0.46

Sarkozy et al., 2003 (9)

Italian

8/71 (11.2%)

0.41

9/71 (12.6%)

0.68

Zenker et al., 2004 (19)

Germany

17/57 (29.8%)

0.53

9/57 (15.8%)

0.44

Yoshida et al., 2004 (20)

Japanese

12/45 (26.6%)

0.73

3/45 (6.6%)

1

Niihori et al., 2005 (18)

Japanese

10/41 (24.4%)

0.91

1/41 (2.4%)

0.48

Bertola et al., 2006 (13)

Brazilian

9/50 (18%)

1

4/50 (8%)

1

Hung et al., 2007 (12)

Taiwanese

6/34 (17.6%)

1

2/34 (5.8%)

1

Ferrero et al., 2008 (21)

Italian

4/40 (10%)

0.39

2/40 (5%)

1

Ko et al., 2008 (22)

Korean

6/59 (10.1%)

0.39

3/59 (5.1%)

1

Lee et al., 2011 (11)

Korean

9/59 (15.2%)

0.71

5/59 (8.4%)

1

Our study

Moroccan

3/16 (18.75%)

-

1/16 (6.25%)

-

Compared to our study.

a

syndrome, cardiofaciocutaneous (CFC) syndrome,
Costello syndrome, etc.) that show a number of the same
traits. Some of those syndromes also share the genetic
causes of Noonan syndrome, such as Leopard syndrome,
which is considered as an allelic condition of Noonan
syndrome (28). Previous studies established differential
diagnosis guidelines that could be very useful to distinguish
Noonan syndrome from the others (29).
4.4. Genetic counseling
Although Noonan syndrome is a dominant disorder
caused by germline mutations, the fact that, on the one
hand, it is genetically heterozygous and, on the other
hand, it is almost always due to de novo mutations makes
the quality of life much better for both the parents and
the patient him/herself. Indeed, the heterozygosity of
this disorder suggest that its inheritance from affected
individuals to offspring remains limited at 50% for each
pregnancy and could be easily avoid by preimplantation
genetic diagnosis. Furthermore, de novo mutation implies
that, for the parents, the risk of recurrence in an upcoming
child remains theoretically very low, about 1%–5%.
Previous studies demonstrated that PTPN11 germline
mutations are present in 50% of Noonan syndrome cases,
while PTPN11 somatic mutations are observed in 34%
of patients with nonsyndromic juvenile myelomonocytic
leukemia (JMML). However, some Noonan syndrome
cases associated with leukemia, especially JMML, were
reported to be caused by somatic PTPN11 mutations, but
rarely as germline transmission (30).
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Moreover, the mutation-positive subjects for whom
diagnosis was confirmed by the present PTPN11 mutations
screening could receive appropriate genetic counseling
and be followed by suitable multidisciplinary medical
teams, even preventing likely subsequent complications.
The present study allowed, for the first time, the
identification of exon 3 and 8 PTPN11 mutations in a
Moroccan cohort. We found 3 heterozygous mutations
(Asp61Gly, Tyr63Cys, and Asn308Ser). The rate of
mutation in our cohort did not differ from those of
other populations. The mutation-positive patients got
appropriate genetic counseling. The screening of the
remaining exons is already underway in order to gain a
full view about the spectrum of mutations in Moroccan
children with Noonan syndrome.
Finally, it is important to mention that PTPN11 is
certainly the first genetic cause of Noonan syndrome
manifestation, but not the last. Indeed, subsequent studies
have proven the involvement of other genes from the
same molecular signaling cascade (RAS–MAP kinase),
although with less frequency, such as SOS1 (31), the RAF
family (32), and the RAS family (33), which will be surely
interesting to explore in the Moroccan population.
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